financial guidance

The firm provided full-year 2018 revenue and adjusted earnings guidance that fell below Wall Street's expectations.

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

Based on the growth in test volume and revenue, the company increased its volume and revenue guidance for the year.

Rapid immunoassay product revenues — including sales from the firm's QuickVue, Sofia, and Eye Health products — rose 40 percent year over year.

Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.

Although revenues from the firm's global diagnostics business were down 6 percent year over year, molecular diagnostic product revenues were up 6 percent.

In 2018, the company expects to place between 140 and 170 new ePlex analyzers, and an annuity per ePlex in the $100,000 to $120,000 range.

The company said it also saw record cash collections in the quarter despite challenges caused by regulatory change.

The company said revenues in its diagnostics business unit rose 62 percent during the quarter.

The company said test volume rose 87 percent to 186,000 during the quarter.